ClinConnect ClinConnect Logo
Search / Trial NCT06972472

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

Launched by ELI LILLY AND COMPANY · May 7, 2025

Trial Information

Current as of July 24, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying a medication called orforglipron to see how well it helps people with obesity or overweight who also have type 2 diabetes manage their blood sugar levels. Participants will be compared to a group receiving a placebo, which is a treatment that looks like the medication but doesn’t actually contain any active ingredients. The trial will last about 18 months, and it aims to find out if orforglipron can improve how well participants control their diabetes.

To be eligible for this study, participants need to be adults aged 65 to 74 with a body mass index (BMI) of 25 or higher, indicating they are overweight or obese. They must also have type 2 diabetes and a specific blood sugar level. People who have type 1 diabetes, unstable weight changes recently, or certain heart or liver conditions cannot participate. If you join the trial, you'll be part of an important effort to find new ways to help manage diabetes and weight, and you'll receive regular check-ups to monitor your health throughout the study.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Have body mass index (BMI) ≥25 kilograms per square meter (kg/m2) at screening
  • Have type 2 diabetes
  • Have hemoglobin A1c (HbA1c) ≥7% and ≤10% at screening
  • Have a history of at least one unsuccessful dietary effort to lose body weight
  • Exclusion Criteria:
  • Have type 1 diabetes
  • Have an unstable body weight within 90 days prior to screening
  • Have New York Heart Association functional classification IV congestive heart failure or an acute cardiovascular condition within 90 days prior to screening
  • Have acute or chronic hepatitis or pancreatitis
  • Are taking other medications or alternative remedies to manage weight loss

About Eli Lilly And Company

Eli Lilly and Company is a global healthcare leader dedicated to creating innovative medicines that improve patient outcomes across a range of therapeutic areas, including diabetes, oncology, immunology, and neurodegenerative diseases. With a rich history of scientific research and a commitment to advancing healthcare, Lilly invests significantly in clinical trials to develop new treatments and enhance existing therapies. The company prioritizes patient safety and ethical standards in its clinical research, fostering collaboration with healthcare professionals and stakeholders to ensure the delivery of high-quality, evidence-based solutions that address unmet medical needs worldwide.

Locations

Buenos Aires, , Argentina

Corvallis, Oregon, United States

Woodstock, Georgia, United States

Beijing, Beijing, China

Harbin, Heilongjiang, China

Tianjin, Tianjin, China

Beijing, Beijing, China

Chengdu, Sichuan, China

Rockville, Maryland, United States

Meridian, Idaho, United States

Smithfield, Pennsylvania, United States

New Delhi, Delhi, India

Chapel Hill, North Carolina, United States

Nanjing, Jiangsu, China

Uherske Hradiste, , Czechia

Nanjing, Jiangsu, China

Philadelphia, Pennsylvania, United States

Yokohama, Kanagawa, Japan

Chuo Ku, Tokyo, Japan

Jinan, Shandong, China

Guangzhou, Guangdong, China

Houston, Texas, United States

Deland, Florida, United States

Chuo Ku, Tokyo, Japan

Bhubaneswar, Odisha, India

Oldenburg, Schleswig Holstein, Germany

San Pedro Garza Garcia, , Mexico

Hefei, Anhui, China

Essen, Nordrhein Westfalen, Germany

Mérida, , Mexico

Chongqing, Chongqing, China

Beijing, Beijing, China

Chitose, Hokkaido, Japan

Suita Shi, Osaka, Japan

Uherske Hradiste, Zlínský Kraj, Czechia

Shavano Park, Texas, United States

Pune, Maharashtra, India

Praha, Praha 4, Czechia

Essen, Nordrhein Westfalen, Germany

Leipzig, Sachsen, Germany

Chuo Ku, Tokyo, Japan

Merida, Yucatán, Mexico

Luoyang Shi, Henan, China

Missoula, Montana, United States

Shinjuku Ku, Tokyo, Japan

Yamato Shi, Kanagawa, Japan

Rosario, Santa Fe, Argentina

San Pedro Garza Garcia, Nuevo León, Mexico

Ushiku, Ibaraki, Japan

San Ramon, California, United States

Mihama Ku,Chiba City, Chiba, Japan

Santa Fe, , Argentina

Tampa, Florida, United States

Dallas, Texas, United States

Savannah, Georgia, United States

Ceske Budejovice, Jihočeský Kraj, Czechia

Leipzig, Sachsen, Germany

Guwahati, Assam, India

Hubli, Karnataka, India

Tokyo, , Japan

Tucson, Arizona, United States

Hamburg, , Germany

Tsuchiura, Ibaraki, Japan

Charlotte, North Carolina, United States

český Krumlov, , Czechia

Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina

Caba, Ciudad Autónoma De Buenos Aires, Argentina

Fayetteville, North Carolina, United States

Ciudad Autónoma De Buenos Aires, Buenos Aires, Argentina

Chihuahua, , Mexico

Dorado, , Puerto Rico

Thousand Oaks, California, United States

Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina

Hollywood, Florida, United States

Guaynabo, , Puerto Rico

Santa Ana, California, United States

Hyderabad, Telangana, India

Rishikesh, Uttarakhand, India

Mexico City, Distrito Federal, Mexico

Decatur, Georgia, United States

Mérida, Yucatán, Mexico

Ostrava, Moravskoslezský Kraj, Czechia

Fort Lauderdale, Florida, United States

Ocoee, Florida, United States

Decatur, Georgia, United States

New Iberia, Louisiana, United States

Silver Spring, Maryland, United States

Carson City, Nevada, United States

Las Vegas, Nevada, United States

Mission, Texas, United States

Munich, Bayern, Germany

Takamatsu, Kagawa, Japan

Mexico, Distrito Federal, Mexico

Guadalajara, Jalisco, Mexico

Decatur, Georgia, United States

Buenos Aires, , Argentina

Ceske Budejovice, , Czechia

Merida, , Mexico

Caba, , Argentina

Praha, , Czechia

Ostrava, , Czechia

Chitose, Hokkaido, Japan

Patients applied

0 patients applied

Trial Officials

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Study Director

Eli Lilly and Company

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported